TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31600414
Drug: Internet-delivered mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered mindfulness-based cognitive therapy (iMBCT)
Study: 31119881
Drug: Daily self-weighing
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-weighing (DSW) with visual graphical feedback (GF)
Study: 16395260
Drug: FK352 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK352 (50 mg, intravenous)
Study: 9008601
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections at the same time frequency
Study: 8497357
Drug: Standard skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard skin preparation plus normal saline irrigation
Study: 8497357
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation plus antibiotic irrigation
Study: 8497357
Drug: Special preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special preparation plus normal saline irrigation
Study: 8497357
Drug: Special preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special preparation plus antibiotic irrigation
Study: 28660739
Drug: 12 SQ
Normalized name: ODACTRA 12 SQ-HDM Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 SQ HDM sublingual immunotherapy tablet
Study: 25694217
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg/day) for 6 weeks
Study: 23775581
Drug: Deferasirox (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (mean dose 9.8 ± 3.6 mg/kg/day)
Study: 23775581
Drug: Deferasirox (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (mean dose in extension 13.7 ± 4.6 mg/kg/day)
Study: 16575712
Drug: Medical Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Training Therapy (MTT)
Study: 11851735
Drug: Spasticity management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spasticity management (intramuscular injections of phenol, alcohol, and botulinum toxin type A)
Study: 9517912
Drug: Milnacipran (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (50 mg twice daily)
Study: 9517912
Drug: Imipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50 mg twice daily)
Study: 22713081
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine (CHX) gel and 304% fluoride toothpaste
Study: 22713081
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (twice daily toothbrushing with toothpaste only)
Study: 18971385
Drug: Only conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only conventional therapy (control group)
Study: 18971385
Drug: Only FES
Normalized name: Product containing only fesoterodine (medicinal product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only FES therapy (chronic group)
Study: 9496386
Drug: Epirubicin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin monotherapy every two weeks (110 mg/m2) with filgrastim (5 micrograms/kg/daily) prophylactically on days 2‐12 of each cycle
Study: 9496386
Drug: Epirubicin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin monotherapy every four weeks (110 mg/m2) with filgrastim (5 micrograms/kg/daily) prophylactically on days 2‐12 of each cycle
Study: 9496386
Drug: Epirubicin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin monotherapy every two weeks
Study: 9496386
Drug: Epirubicin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin monotherapy every four weeks
Study: 8369939
Drug: Single-dose cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose cefuroxime (1.5 g intravenously before operation)
Study: 8369939
Drug: Three-dose cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose cefuroxime regimen (1.5 g before and two doses of 0.75 g after operation)
Study: 20090676
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg oral dosing)
Study: 20090676
Drug: Erythromycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (125 mg intravenous dosing)
Study: 12800418
Drug: Jiawei Mojie
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jiawei Mojie Tablet (JMT)
Study: 11249645
Drug: MFG‐IRAP gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFG‐IRAP gene therapy
Study: 8888384
Drug: Flesinoxan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flesinoxan (up to 2.4 mg per day)
Study: 8888384
Drug: Flesinoxan (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flesinoxan (0.6 or 1.2 mg/day)
Study: 1804665
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 40 mg.day-1
Study: 1804665
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate 500 micrograms t.d.s.
Study: 6358156
Drug: Irradiation combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation combined with misonidazole (1 gr/m2, total dose 12 gr/m2)
Study: 26952645
Drug: Internet Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet Cognitive Behavioral Therapy (MumMoodBooster program)
Study: 21044434
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) in combination with other DMARDs (e.g., leflunomide, cyclosporine, azathioprine, sulfasalazine, gold, hydroxychloroquine)
Study: 21044434
Drug: Early use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early use of biologics
Study: 11916808
Drug: S(+)‐ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine (0.5 mg/kg bolus before incision, followed by 2 microg x kg(‐1) x min(‐1) infusion until 2 h after emergence from anesthesia)
Study: 1549961
Drug: Alendronate, 10
Normalized name: Alendronate, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate, 10 mg/day for 5 days
Study: 19050436
Drug: Intraarterial autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial autologous BMCs with oral antioxidants and L-arginine
Study: 19050436
Drug: Maximal drug
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal drug therapy (control group)
Study: 12934760
Drug: Walnut oil
Normalized name: Walnut oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut oil (3 g/day in 500 mg capsules) for 45 days
Study: 10651694
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course therapy (multiple courses of 12 weeks)
Study: 10651694
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (1 year)
Study: 10651694
Drug: Both short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both short course and continuous therapy
Study: 8880657
Drug: Interactional couples
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactional couples therapy
Study: 8880657
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three treatments (BMT, interactional therapy, individual counseling)
Study: 1668960
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acyclovir t.d. for 6 months
Study: 27973619
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg/d
Study: 25352484
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy after intravenous r‐tPA
Study: 25352484
Drug: Intravenous r‐tPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous r‐tPA alone
Study: 9065316
Drug: Tramazoline aerosol
Normalized name: tramazoline
DrugBank: Tramazoline (DB13064)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramazoline aerosol (Rhinospray) 0.14 mg
Study: 9065316
Drug: Tramazoline aerosol
Normalized name: tramazoline
DrugBank: Tramazoline (DB13064)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramazoline aerosol (Rhinospray) 0.19 mg
Study: 1683882
Drug: Noberastine (NOB)
Normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noberastine (NOB) 10 mg
Study: 1683882
Drug: Noberastine (NOB)
Normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noberastine (NOB) 20 mg
Study: 1683882
Drug: Noberastine (NOB)
Normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noberastine (NOB) 30 mg
Study: 1683882
Drug: Noberastine (NOB)
Normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noberastine (NOB) 10, 20, and 30 mg
Study: 31077168
Drug: Telephone cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone cognitive behavioural therapy (tCBT)
Study: 22282432
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravenous psilocybin
Study: 14526453
Drug: nCPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP therapy
Study: 14526453
Drug: No nCPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nCPAP therapy (untreated group)
Study: 10898689
Drug: Stavudine 40
Normalized name: stavudine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 40 mg single dose in subjects with mild renal impairment (CL(CR) 60 to 80)
Study: 10898689
Drug: Stavudine 40
Normalized name: stavudine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 40 mg single dose in subjects with moderate renal impairment (CL(CR) 30 to 50)
Study: 10898689
Drug: Stavudine 40
Normalized name: stavudine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 40 mg single dose in subjects with severe renal impairment (CL(CR) </=20)
Study: 10898689
Drug: Stavudine dosage
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine dosage recommendations for renal impairment (for subjects weighing >/=60 kg)
Study: 10898689
Drug: Stavudine dosage
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine dosage recommendations for renal impairment (for subjects weighing <60 kg)
Study: 8836274
Drug: Topical lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lignocaine 40 mg/ml (4 ml, < or = 3 mg/kg)
Study: 8836274
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (4 ml)
Study: 1417068
Drug: Fish-oil supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil supplements over a 4-week period
Study: 6239884
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg) + Tetracycline (250 mg) four times daily
Study: 6239884
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg) + Placebo four times daily
Study: 6239884
Drug: Tetracycline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (250 mg) + Placebo four times daily
Study: 6239884
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Placebo four times daily
Study: 23577062
Drug: Biojector® 2000™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biojector® 2000™ delivery of DNA vaccine (VRC-HIVDNA016-00-VP)
Study: 23577062
Drug: Needle and
Normalized name: syringe with needle and cannula, disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle and syringe (N/S) delivery of DNA vaccine (VRC-HIVDNA016-00-VP)
Study: 16686722
Drug: Open-label solifenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label solifenacin treatment
Study: 11344197
Drug: ovine corticotropin-releasing
Normalized name: Ovine corticotropin-releasing factor
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ovine corticotropin-releasing hormone (oCRH)
Study: 7974297
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 x 8 mg/day)
Study: 29429455
Drug: Rehabilitation intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rehabilitation intervention (early rehabilitation including oral sensory and muscle strength training, pressure touching of head, chest, abdomen, extremities, hands, and feet)
Study: 23153049
Drug: Straight injection
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Straight injection (SI)
Study: 23153049
Drug: Oblique injection
Normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oblique injection (OI)
Study: 23153049
Drug: Double-plane tunnel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-plane tunnel injection (DPTI)
Study: 15815120
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker intervention (n=124)
Study: 11752510
Drug: Willow bark
Normalized name: Willow bark
DrugBank: Willow bark (DB14691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willow bark extract (Assalix) - 240 mg of salicin daily
Study: 11752510
Drug: Rofecoxib -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib - 12.5 mg daily
Study: 3240887
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g oxytetracycline hydrochloride
Study: 29898671
Drug: Sit-to-stand exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sit-to-stand exercise performed at four occasions daily and a protein-rich oral supplement, twice a day for 12 weeks.
Study: 25115659
Drug: Intrusion force
Normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrusion force of 60 g applied for 21 days on experimental group premolars
Study: 22261129
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of misoprostol (400 μg every 6 hours, up to 4 doses)
Study: 22261129
Drug: Misoprostol plus
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol plus oxytocin (initial 600 μg vaginal misoprostol followed by intravenous oxytocin)
Study: 20309628
Drug: Cyclophosphamide-containing adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide-containing adjuvant chemotherapy
Study: 12076912
Drug: Radiofrequency ablation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency ablation + 20 mg IV doxorubicin (Doxil) 24 hr before ablation
Study: 8583136
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2b therapy at a dose of 5 MU administered daily until a response was achieved (minimum 6 months or maximum 1 year).
Study: 2654215
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid cream applied twice daily until clearing was achieved
Study: 2654215
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice daily until clearing was achieved
Study: 116053
Drug: Irrigor (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigor (30 to 150 mg daily, administered in tablets, intramuscularly, and intravenously)
Study: 116053
Drug: Irrigor (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigor (administered in courses, single intravenous infusion, double blind method)
Study: 116053
Drug: Irrigor (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigor (administered intramuscularly and intravenously)
Study: 31090434
Drug: Xiaoaiping injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoaiping injections (1 dose/day for 10 days) with chemotherapy
Study: 28437787
Drug: 0.6 mL∙kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mL∙kg‐1 of 0.25% levobupivacaine
Study: 28437787
Drug: 0.8 mL∙kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mL∙kg‐1 of 0.25% levobupivacaine
Study: 28437787
Drug: 1.0 mL∙kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL∙kg‐1 of 0.25% levobupivacaine
Study: 21323688
Drug: Dried plums
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried plums (50 g b.d., fibre=6 gm/day)
Study: 21323688
Drug: Psyllium (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (11 g b.d., fibre=6 gm/day)
Study: 10618942
Drug: Esmolol 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 80 mg i.v.
Study: 1742224
Drug: Batanopride (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batanopride (0.2 to 6.0 mg/kg)
Study: 1742224
Drug: Batanopride (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batanopride (highest dose group)
Study: 1742224
Drug: Methylprednisolone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (250 mg)
Study: 7178821
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA) 1000 mg/day
Study: 7178821
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 1000 mg/day
Study: 16943370
Drug: Rizatriptan 5
Normalized name: rizatriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 5 mg (for body weight 20 to 39 kg)
Study: 16943370
Drug: Rizatriptan 10
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 10 mg (for body weight 40 kg or more)
Study: 2856893
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral nadolol o.d.
Study: 2856893
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oral nadolol o.d.
Study: 2856893
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg oral nadolol o.d.
Study: 2856893
Drug: 0.25% topical
Normalized name: Remyda, 0.25% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% topical timolol b.d.
Study: 2856893
Drug: 0.5% topical
Normalized name: Carac 0.5% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% topical timolol b.d.
Study: 2856893
Drug: Oral nadolol
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nadolol (various doses)
Study: 2856893
Drug: Long-term therapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term therapy with oral nadolol
Study: 29895289
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV morphine
Study: 24179986
Drug: Rocatec group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocatec group (Rocatec treatment and silane application)
Study: 24179986
Drug: Ultrasonic-Rocatec group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic-Rocatec group (Rocatec treatment followed by ultrasonic cleaning and silanization)
Study: 23245940
Drug: Essex cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essex cream
Study: 17768173
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (Ciclosporin + Prednisolone)
Study: 12454761
Drug: Fulvestrant 125
Normalized name: fulvestrant 125 MG per 2.5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 125 mg
Study: 10379016
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil diet (0.5 g trans fatty acid per 100 g fat)
Study: 10379016
Drug: Semiliquid margarine
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semiliquid margarine diet (0.5 g trans fatty acid per 100 g fat)
Study: 10379016
Drug: Soft margarine
Normalized name: Soft margarine not polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft margarine diet (7.4 g trans fatty acid per 100 g fat)
Study: 10379016
Drug: Shortening diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortening diet (9.9 g trans fatty acid per 100 g fat)
Study: 10379016
Drug: Stick margarine
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stick margarine diet (20.1 g trans fatty acid per 100 g fat)
Study: 2282972
Drug: Sultamicillin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sultamicillin (50 mg/kg.day or 500 mg/day)
Study: 2282972
Drug: Amoxycillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (40 mg/kg.day or 250 mg/day)
Study: 6815695
Drug: IV L-tryptophan
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV L-tryptophan (TRP)
Study: 31551370
Drug: BCG and
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG and oral polio vaccine (OPV) administered at a single home visit
Study: 22154318
Drug: In-treatment heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment heart rate (HR)
Study: 22154318
Drug: In-treatment HR
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment HR of ≥84 beats/min
Study: 19670055
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus risperidone (CogTher + Risp)
Study: 19670055
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus placebo (CogTher + Placebo)
Study: 17138722
Drug: ID fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID fat infusion with orlistat (120 mg)
Study: 15200654
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg x kg(‐1) morphine hydrochloride (M)
Study: 15200654
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg x kg(‐1) tramadol hydrochloride (T)
Study: 15200654
Drug: 0.5 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg(‐1) ketamine hydrochloride (K)